Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790001 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
PNI was an independently significant predictor of adverse survival outcomes in this large institutional cohort, particularly for patients with NCCN low-risk disease. PNI should be carefully considered along with other standard prognostic factors when treating these patients with EBRT. Supplementing EBRT with ADT may be beneficial for select low-risk patients with PNI though independent validation with prospective studies is recommended.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Luke C. M.D., Amol K. M.D., Carol B.A., Noura A. M.D., Peijin M.D., M.H.S., Ariel E. M.D., Scott P. Ph.D., Pei Ph.D., Janson B.S., Ashwin N. M.D., Todd R. Ph.D., Emily B.A., Theodore A. B.A., Stephanie Honig, Harleen B.A., Stephen C. M.D., Phuoc T. M.D.,